{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:40:11Z","timestamp":1780623611125,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cca.2023.117689","type":"journal-article","created":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T18:32:10Z","timestamp":1701628330000},"page":"117689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Dried blood spot analysis for the quantification of vancomycin and creatinine using liquid chromatography \u2013 tandem mass spectrometry: Method development and validation"],"prefix":"10.1016","volume":"553","author":[{"given":"Soma","family":"Bahmany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moska","family":"Hassanzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein A.W.","family":"van Onzenoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cca.2023.117689_b0005","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1001\/archinte.1988.00380100037008","article-title":"Acute interstitial nephritis associated with vancomycin therapy","volume":"148","author":"Bergman","year":"1988","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.cca.2023.117689_b0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0002-9343(87)90947-8","article-title":"Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy","volume":"83","author":"Cimino","year":"1987","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.cca.2023.117689_b0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"Rybak","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.cca.2023.117689_b0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7326\/0003-4819-95-4-458","article-title":"Vancomycin Ototoxicity in patient with normal renal function","volume":"95","author":"Traber","year":"1981","journal-title":"Ann. Intern. Med."},{"issue":"19","key":"10.1016\/j.cca.2023.117689_b0025","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.cca.2023.117689_b0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.cca.2023.117689_b0035","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.cca.2023.117689_b0040","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.cca.2023.117689_b0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijantimicag.2011.08.017","article-title":"Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study","volume":"39","author":"Li","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2","key":"10.1016\/j.cca.2023.117689_b0050","first-page":"91","article-title":"Monitoring of serum vancomycin concentrations in pediatric patients with normal renal function","volume":"48","author":"Khotaei","year":"2010","journal-title":"Acta Med. Iran."},{"issue":"11","key":"10.1016\/j.cca.2023.117689_b0055","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.arcped.2008.08.016","article-title":"[Monitoring serum vancomycin concentrations in the treatment of Staphylococcus infections in children] Surveillance des taux seriques de vancomycine dans le traitement des infections a staphylocoque en pediatrie","volume":"15","author":"Mariani-Kurkdjian","year":"2008","journal-title":"Arch Pediatr"},{"issue":"2","key":"10.1016\/j.cca.2023.117689_b0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1413-8670(10)70041-6","article-title":"Vancomycin: the need to suit serum concentrations in hemodialysis patients","volume":"14","author":"Marengo","year":"2010","journal-title":"Braz. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.cca.2023.117689_b0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00007691-199706000-00004","article-title":"Special considerations for monitoring vancomycin concentrations in pediatric patients","volume":"19","author":"Miles","year":"1997","journal-title":"Ther. Drug Monit."},{"issue":"8","key":"10.1016\/j.cca.2023.117689_b0070","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.medmal.2011.01.012","article-title":"[Monitoring vancomycin in an intensive care unit: A retrospective survey on 66 patients] Monitorage de la vancomycine en reanimation: etude retrospective de 66 patients","volume":"41","author":"Commandeur","year":"2011","journal-title":"Med Mal Infect"},{"issue":"4","key":"10.1016\/j.cca.2023.117689_b0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2223\/JPED.617","article-title":"[Monitorization of blood levels of vancomycin in children with multi-resistant bacterial infections] Monitorizacao das concentracoes sericas da vancomicina em criancas com infeccoes por bacterias multiresistentes","volume":"72","author":"Reis","year":"1996","journal-title":"J Pediatr (Rio J)"},{"issue":"3","key":"10.1016\/j.cca.2023.117689_b0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jac\/45.3.329","article-title":"High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures","volume":"45","author":"Pea","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.cca.2023.117689_b0085","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.medmal.2011.09.014","article-title":"Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia","volume":"41","author":"Hochart","year":"2011","journal-title":"Med. Mal. Infect."},{"issue":"5","key":"10.1016\/j.cca.2023.117689_b0090","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1345\/aph.1P588","article-title":"Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients","volume":"45","author":"Eiland","year":"2011","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.cca.2023.117689_b0095","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.cca.2023.117689_b0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J. Infect. Chemother."},{"issue":"1","key":"10.1016\/j.cca.2023.117689_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","article-title":"Vancomycin: a review of population pharmacokinetic analyses","volume":"51","author":"Marsot","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.cca.2023.117689_b0110","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/FTD.0000000000000994","article-title":"Best practices to implement dried blood spot sampling for therapeutic drug monitoring in clinical practice","volume":"44","author":"Francke","year":"2022","journal-title":"Ther. Drug Monit."},{"issue":"13\u201314","key":"10.1016\/j.cca.2023.117689_b0115","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.clinbiochem.2016.05.004","article-title":"Dried blood spots analysis with mass spectrometry: Potentials and pitfalls in therapeutic drug monitoring","volume":"49","author":"Antunes","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2023.117689_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121897","article-title":"Vancomycin and creatinine determination in dried blood spots: Analytical validation and clinical assessment","volume":"1137","author":"Scribel","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.cca.2023.117689_b0125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FTD.0000000000000411","article-title":"Dried blood spots combined with ultra\u2013high-performance liquid chromatography\u2013mass spectrometry for the quantification of the antipsychotics risperidone, aripiprazole, pipamperone, and their major metabolites","volume":"39","author":"Tron","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.cca.2023.117689_b0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/FTD.0000000000000984","article-title":"Development and validation of a dried blood spot assay using UHPLC-MS\/MS to Identify and quantify 12 antihypertensive drugs and 4 active metabolites: clinical needs and analytical limitations","volume":"44","author":"Peeters","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2023.117689_b0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2022.08.014","article-title":"The clinical validation of a dried blood spot method for simultaneous measurement of cyclosporine A, tacrolimus, creatinine, and hematocrit","volume":"535","author":"Francke","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2023.117689_b0140","unstructured":"C.a.L.S. Institute, Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures 25(Second Edition) (2006)."},{"key":"10.1016\/j.cca.2023.117689_b0145","unstructured":"E.M. Agency, Guideline on bioanalytical method validation (2011)."},{"key":"10.1016\/j.cca.2023.117689_b0150","unstructured":"U.S.D.o.H.a.H. Services, Bioanalytical Method Validation Guidance for Industry (2018)."},{"issue":"4","key":"10.1016\/j.cca.2023.117689_b0155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2023.117689_b0160","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2017.04.003","article-title":"New liquid chromatography-tandem mass spectrometry method for routine TDM of vancomycin in patients with both normal and impaired renal functions and comparison with results of polarization fluoroimmunoassay in light of varying creatinine concentrations","volume":"469","author":"Brozmanova","year":"2017","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.cca.2023.117689_b0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00007691-198909000-00017","article-title":"Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients","volume":"11","author":"Anne","year":"1989","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2023.117689_b0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinbiochem.2019.06.011","article-title":"Ready for TDM: Simultaneous quantification of amikacin, vancomycin and creatinine in human plasma employing ultra-performance liquid chromatography-tandem mass spectrometry","volume":"70","author":"da Silva","year":"2019","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2023.117689_b0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jpba.2018.12.023","article-title":"Simultaneous determination of vancomycin and creatinine in plasma applied to volumetric absorptive microsampling devices using liquid chromatography-tandem mass spectrometry","volume":"165","author":"Andriguetti","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.cca.2023.117689_b0180","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jpba.2007.02.006","article-title":"Recent advances in high-throughput quantitative bioanalysis by LC-MS\/MS","volume":"44","author":"Xu","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2023.117689_b0185","first-page":"1","article-title":"Dried blood spot sampling for therapeutic drug monitoring: challenges and opportunities","author":"Muller","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.cca.2023.117689_b0190","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00216-014-8415-2","article-title":"Dried blood spot analysis of creatinine with LC-MS\/MS in addition to immunosuppressants analysis","volume":"407","author":"Koster","year":"2015","journal-title":"Anal. Bioanal. Chem."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123004916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:11:28Z","timestamp":1757862688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123004916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"alternative-id":["S0009898123004916"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117689","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dried blood spot analysis for the quantification of vancomycin and creatinine using liquid chromatography \u2013 tandem mass spectrometry: Method development and validation","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117689"}}